LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patients - Trial NCT06109883
Access comprehensive clinical trial information for NCT06109883 through Pure Global AI's free database. This Phase 1 trial is sponsored by The Netherlands Cancer Institute and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 43 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Netherlands Cancer Institute
Timeline & Enrollment
Phase 1
Apr 01, 2024
Nov 01, 2026
Primary Outcome
The recommended phase II dose of LB-100 and azenosertib
Summary
This Phase Ib trial studies the side effects and best dose of LB-100 and azenosertib for the
 treatment of patients with metastatic colorectal cancer. Azenosertib blocks a protein that is
 involved in the repair of damaged DNA, this protein is called WEE1. Inhibiting WEE1 drives
 cancer cells into a state of cell division without repair of the damaged DNA, resulting in
 cell death. LB-100 has been shown to make anticancer drugs work better at killing cancer.
 LB-100 blocks a protein called PP2A. Blocking this protein increases the stress signals for
 the tumor cells that express PP2A. Research has shown that azenosertib and LB-100 may enhance
 each others effect when treating metastatic colorectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06109883
Non-Device Trial